Replies to post #389310 on NorthWest Biotherapeutics Inc (NWBO)

[Mionaer1]

Great DD. Thank you!

[Dr Bala]

Great post, sharpie.

[Doc logic]

sharpie510,

Thanks for sharing this. This is just one more point of evidence that everything that has been learned in the last 14 years in this trial is going into the exhaustive and groundbreaking effort to better understand and properly treat GBM patients and the case is being made for L being SOC in that effort. Best wishes.

[VikingInvest]

Thanks for all your DD, Sharpie. And thanks to all who are contributing to the discussion.

[ATLnsider]

I agree sharpie510

[Bacchus1]

Thank you Sharpie

[biosectinvestor]

Thanks so much Sharpie! Great stuff you’re posting, and others too!

[sentiment_stocks]

Sharpie, thank you for all this wonderful DD and background on this topical IDH issue. It's all looking very bullish.

I do want to suggest, though, that I doubt the top line data, or probably even the journal presentation, will go into any sort of depth (or even address) the topic of GBM subtypes like mesenchymal, classical or pro neural. Those subtypes were not called out in the protocol, and are not indicated to be measured in the indicated SAP endpoints. Even IDH mutant or IDH wild type status were not part of the protocol. It's possible that it may receive some sort of mention in the journal, but a deeper analysis will likely be addressed in some sort of future white paper.

The clinical journals have moderately strict limits as to the word counts they'll allow for a manuscript, and there's a lot of trial analysis and discussion (such as external control arms and pseudo progression) they are likely to want to cover that will eat up that word count pretty quickly.

NEJM has one of the smallest word limits with 2700 in the main text (250 in the abstract), and the BMJ has one of the higher at 4400 (400 in the abstract).

[eagle8]

Great post sharpie, thank you.

pGBM (Mesenchymal/classical) survival curve, Up and to the RIGHT !

Looking extremely good for DCvax !

Best to you.

[newman2021]

sharpie,

what is the mOS for DcVaxL and control patients in the second chart of mesencymal (IDH wild) patients that Dr. L is presenting. Looks to me the difference in mOS could be small but the difference between the tail is huge meaning OS extending beyond the mOS for years 2,3,4,5 is huge. Looks to me the tail is very beneficial.

Thanks for your excellent DD.